Story perspectives

FDA Cracks Down on Misleading Drug Ads Following Trump Directive

9/17/2025

Summary

Story summary

The FDA is increasing oversight on direct-to-consumer pharmaceutical advertisements following President Trump's directive to combat misleading marketing.
It issued nearly 70 warning letters, focusing on online pharmacies and major drugmakers like Eli Lilly and AstraZeneca.
AstraZeneca's FluMist ad was flagged as "false or misleading" for its portrayal of minors and lack of risk information.
Companies must respond within 15 days, with potential legal action for non-compliance.
The FDA seeks to enhance clarity in drug risk and benefit communication in advertising.

History

Historical Context

The Kefauver-Harris Amendment of 1962 transformed drug regulation by requiring proof of efficacy alongside safety for new drugs, a response to the thalidomide tragedy. Recently, the FDA issued 70 warning letters to companies like Eli Lilly and AstraZeneca, reinforcing compliance with advertising standards. This increased oversight aligns with President Trump's directive to combat misleading marketing practices, crucial for public health and trust in pharmaceuticals.

1 of 2

Story summary

The FDA is increasing oversight on direct-to-consumer pharmaceutical advertisements following President Trump's directive to combat misleading marketing.
It issued nearly 70 warning letters, focusing on online pharmacies and major drugmakers like Eli Lilly and AstraZeneca.
AstraZeneca's FluMist ad was flagged as "false or misleading" for its portrayal of minors and lack of risk information.
Companies must respond within 15 days, with potential legal action for non-compliance.
The FDA seeks to enhance clarity in drug risk and benefit communication in advertising.

1 / 2